Stock PRAX PRAXIS PRECISION MEDICINES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
54.87 USD -3.50% Intraday chart for Praxis Precision Medicines, Inc. +12.35% +146.27%
Apr. 11 Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024. CI
Apr. 11 Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024. CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response Achieving 100% Response in Treated Patients
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Praxis Precision Medicines, Inc. Provides Update on Advancing Clinical Stage Portfolio
CI
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
CI
Praxis Precision Medicines, Inc. Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (PRAX) PRAXIS PRECISION MEDICINES Reports Q2 Revenue $781,000
MT
Praxis Precision Medicines, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Praxis Precision Medicines, Inc. Announces Further Data from Two Additional Analyses of Essential1 Study for Ulixacaltamide
CI
Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
CI
Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-In-Class Profile
CI
Praxis Precision Medicines, Inc. Announces Topline Results from the Essential1 Study of Ulixacaltamide for the Treatment of Essential Tremor and Continued Advancement of Program to Phase 3
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Praxis Precision Medicines, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
CI
Praxis Precision Medicines to Collaborate With UCB For Development of Epilepsy Therapies
MT
Praxis Precision Medicines, Inc. Announces strategic Collaboration with UCB
CI
Praxis Precision Medicines, Inc. to Advance Prax-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRAX Stock
  4. News Praxis Precision Medicines, Inc.
  5. Highlights